Zacks

Zacks Small Cap Research – SWP.TO: Industry Outlook Shows Expected Catalysts for Swiss Water Growth Continuing – Go Health Pro

by
Zacks Small Cap Research – SWP.TO: Industry Outlook Shows Expected Catalysts for Swiss Water Growth Continuing – Go Health Pro

By M. Marin OTC:SWSSF | TSX:SWP.TO READ THE FULL SWP.TO RESEARCH REPORT Rising consumption of ‘decaf’ & specialty coffees important are growth drivers that are expected to continue… British Columbia-based Swiss Water Decaffeinated Coffee Inc. (OTC:SWSSF) (TSX:SWP.TO) is a leading specialty coffee company and premium green coffee decaffeinator focused on producing chemical-free decaffeinated coffee. The … Read more

Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

by
Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal third 2024 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the total to 43. … Read more

Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

by
Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior … Read more

Zacks Small Cap Research – NRXBF: Promising Company Releases Results – Go Health Pro

by

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to … Read more

Zacks Small Cap Research – QSG: F1Q25 Earnings Review: EPS Miss on Lower Revenues; Silver Transition Gaining Momentum – Go Health Pro

by

By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 11/27/24, QuantaSing (NASDAQ:QSG) reported F1Q25 (Sep) earnings results. On a GAAP basis, QSG reported net income of $11.5 million for F1Q25, or $0.21 per ADS. That said, excluding share-based compensation expenses, adjusted EPS came in at $0.23, or below our estimate of … Read more

x